Progyny (PGNY) Competitors

$22.50 -1.22 (-5.13%)

As of 01:46 PM Eastern

PGNY vs. CAI, PACS, RDNT, SHC, and BLLN

Should you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Caris Life Sciences (CAI), PACS Group (PACS), RadNet (RDNT), Sotera Health (SHC), and Billiontoone (BLLN). These companies are all part of the "healthcare" industry.

How does Progyny compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Progyny (NASDAQ:PGNY) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Caris Life Sciences currently has a consensus target price of $27.56, indicating a potential upside of 70.73%. Progyny has a consensus target price of $28.18, indicating a potential upside of 25.24%. Given Caris Life Sciences' higher possible upside, research analysts plainly believe Caris Life Sciences is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Progyny has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	5.62	-$68.09M	-$7.61	N/A
Progyny	$1.29B	1.36	$58.52M	$0.77	29.22

In the previous week, Progyny had 3 more articles in the media than Caris Life Sciences. MarketBeat recorded 28 mentions for Progyny and 25 mentions for Caris Life Sciences. Progyny's average media sentiment score of 0.55 beat Caris Life Sciences' score of -0.02 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Progyny	6 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.9% of Progyny shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Progyny has a net margin of 5.23% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 102.71% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	102.71%	50.55%
Progyny	5.23%	13.34%	9.03%

Summary

Progyny beats Caris Life Sciences on 12 of the 16 factors compared between the two stocks.

How does Progyny compare to PACS Group?

PACS Group (NYSE:PACS) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Progyny had 22 more articles in the media than PACS Group. MarketBeat recorded 28 mentions for Progyny and 6 mentions for PACS Group. Progyny's average media sentiment score of 0.55 beat PACS Group's score of 0.50 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	6 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PACS Group presently has a consensus target price of $44.40, indicating a potential upside of 35.65%. Progyny has a consensus target price of $28.18, indicating a potential upside of 25.24%. Given PACS Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe PACS Group is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

PACS Group has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, Progyny has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Progyny has a net margin of 5.23% compared to PACS Group's net margin of 3.62%. PACS Group's return on equity of 22.55% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	3.62%	22.55%	3.45%
Progyny	5.23%	13.34%	9.03%

PACS Group has higher revenue and earnings than Progyny. PACS Group is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	0.97	$191.54M	$1.23	26.61
Progyny	$1.29B	1.36	$58.52M	$0.77	29.22

94.9% of Progyny shares are owned by institutional investors. 70.1% of PACS Group shares are owned by company insiders. Comparatively, 9.9% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Progyny beats PACS Group on 9 of the 16 factors compared between the two stocks.

How does Progyny compare to RadNet?

Progyny (NASDAQ:PGNY) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

In the previous week, Progyny had 15 more articles in the media than RadNet. MarketBeat recorded 28 mentions for Progyny and 13 mentions for RadNet. Progyny's average media sentiment score of 0.55 beat RadNet's score of 0.49 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	6 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RadNet	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Progyny presently has a consensus price target of $28.18, indicating a potential upside of 25.24%. RadNet has a consensus price target of $88.14, indicating a potential upside of 48.79%. Given RadNet's stronger consensus rating and higher probable upside, analysts plainly believe RadNet is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Progyny has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Progyny has a net margin of 5.23% compared to RadNet's net margin of -0.91%. Progyny's return on equity of 13.34% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
RadNet	-0.91%	2.52%	0.88%

Progyny has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.36	$58.52M	$0.77	29.22
RadNet	$2.04B	2.27	-$18.65M	-$0.25	N/A

94.9% of Progyny shares are owned by institutional investors. Comparatively, 77.9% of RadNet shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 5.6% of RadNet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Progyny beats RadNet on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to Sotera Health?

Progyny (NASDAQ:PGNY) and Sotera Health (NASDAQ:SHC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Sotera Health has lower revenue, but higher earnings than Progyny. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.36	$58.52M	$0.77	29.22
Sotera Health	$1.16B	3.83	$77.94M	$0.41	38.16

In the previous week, Progyny had 7 more articles in the media than Sotera Health. MarketBeat recorded 28 mentions for Progyny and 21 mentions for Sotera Health. Progyny's average media sentiment score of 0.55 beat Sotera Health's score of 0.44 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	6 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sotera Health	3 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.9% of Progyny shares are held by institutional investors. Comparatively, 91.0% of Sotera Health shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Comparatively, 15.4% of Sotera Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Progyny has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Sotera Health has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.

Progyny presently has a consensus price target of $28.18, indicating a potential upside of 25.24%. Sotera Health has a consensus price target of $20.33, indicating a potential upside of 29.97%. Given Sotera Health's higher possible upside, analysts plainly believe Sotera Health is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Sotera Health has a net margin of 9.91% compared to Progyny's net margin of 5.23%. Sotera Health's return on equity of 39.73% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Sotera Health	9.91%	39.73%	7.05%

Summary

Progyny beats Sotera Health on 9 of the 17 factors compared between the two stocks.

How does Progyny compare to Billiontoone?

Progyny (NASDAQ:PGNY) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.36	$58.52M	$0.77	29.22
Billiontoone	$354.54M	13.18	$7.45M	$0.21	484.10

In the previous week, Progyny had 13 more articles in the media than Billiontoone. MarketBeat recorded 28 mentions for Progyny and 15 mentions for Billiontoone. Billiontoone's average media sentiment score of 0.65 beat Progyny's score of 0.55 indicating that Billiontoone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	6 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	1 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny presently has a consensus price target of $28.18, indicating a potential upside of 25.24%. Billiontoone has a consensus price target of $122.43, indicating a potential upside of 20.43%. Given Progyny's stronger consensus rating and higher possible upside, equities analysts plainly believe Progyny is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Progyny has a net margin of 5.23% compared to Billiontoone's net margin of 0.00%. Progyny's return on equity of 13.34% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Billiontoone	N/A	N/A	N/A

Summary

Progyny beats Billiontoone on 13 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.76B	$8.16B	$6.20B	$12.30B
Dividend Yield	N/A	2.86%	2.78%	5.22%
P/E Ratio	29.26	22.66	20.68	25.76
Price / Sales	1.36	16.95	558.03	78.11
Price / Cash	32.22	12.66	27.81	36.27
Price / Book	3.76	4.93	9.82	6.78
Net Income	$58.52M	$183.43M	$3.55B	$333.43M
7 Day Performance	N/A	N/A	N/A	0.49%
1 Month Performance	38.06%	7.30%	6.72%	9.25%
1 Year Performance	6.15%	1.30%	42.70%	43.00%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	4.3763 of 5 stars	$22.50 -5.1%	$28.18 +25.2%	+11.9%	$1.76B	$1.29B	29.26	310	Earnings Report Analyst Forecast
CAI Caris Life Sciences	N/A	$18.69 +1.2%	$28.86 +54.4%	N/A	$5.22B	$812.03M	N/A	1,846	Analyst Forecast
PACS PACS Group	4.0868 of 5 stars	$32.55 -1.4%	$44.40 +36.4%	+221.1%	$5.19B	$5.29B	26.47	47,455	News Coverage Analyst Upgrade
RDNT RadNet	3.0485 of 5 stars	$58.26 +2.5%	$88.14 +51.3%	+4.3%	$4.45B	$2.04B	N/A	11,264	News Coverage Earnings Report Gap Up
SHC Sotera Health	3.6815 of 5 stars	$15.39 -0.7%	$20.67 +34.3%	+20.2%	$4.42B	$1.16B	57.00	3,000	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. CAI, PACS, RDNT, SHC, and BLLN

How does Progyny compare to Caris Life Sciences?

Summary

How does Progyny compare to PACS Group?

Summary

How does Progyny compare to RadNet?

Summary

How does Progyny compare to Sotera Health?

Summary

How does Progyny compare to Billiontoone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. CAI, PACS, RDNT, SHC, and BLLN

How does Progyny compare to Caris Life Sciences?

Do analysts recommend CAI or PGNY?

Which has better valuation & earnings, CAI or PGNY?

Does the media favor CAI or PGNY?

Do insiders & institutionals hold more shares of CAI or PGNY?

Is CAI or PGNY more profitable?

Summary

How does Progyny compare to PACS Group?

Does the media prefer PACS or PGNY?

Do analysts rate PACS or PGNY?

Which has more volatility & risk, PACS or PGNY?

Is PACS or PGNY more profitable?

Which has stronger valuation & earnings, PACS or PGNY?

Do institutionals & insiders believe in PACS or PGNY?

Summary

How does Progyny compare to RadNet?

Does the media favor PGNY or RDNT?

Do analysts recommend PGNY or RDNT?

Which has more volatility and risk, PGNY or RDNT?

Is PGNY or RDNT more profitable?

Which has preferable earnings & valuation, PGNY or RDNT?

Do insiders and institutionals believe in PGNY or RDNT?

Summary

How does Progyny compare to Sotera Health?

Which has better earnings and valuation, PGNY or SHC?

Does the media favor PGNY or SHC?

Do insiders and institutionals believe in PGNY or SHC?

Which has more risk and volatility, PGNY or SHC?

Do analysts recommend PGNY or SHC?

Is PGNY or SHC more profitable?

Summary

How does Progyny compare to Billiontoone?

Which has better earnings and valuation, PGNY or BLLN?

Does the media refer more to PGNY or BLLN?

Do insiders and institutionals believe in PGNY or BLLN?

Do analysts recommend PGNY or BLLN?

Is PGNY or BLLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools